BIOMARKERS VALIDATION LABORATORIES

生物标志物验证实验室

• 批准号: 6133300
• 负责人: DAVID S. CHIA
• 金额: $ 29.6万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-05-16 至 2005-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6133300
• 关键词: biomarker; cancer registry /resource; carcinogenesis; chromosome aberrations; clinical research; cytogenetics; enzyme linked immunosorbent assay; flow cytometry; gene expression; genetic polymorphism; high throughput technology; human subject; immunocytochemistry; in situ hybridization; microarray technology; neoplasm /cancer genetics; tissue resource /registry; tumor antigens; western blottings

The goals for the Biomarker Validation Laboratory-called the UCLA Defined Tumor-Marker Core (D-TEC)-are to: 1. Optimally coordinate a consortium of currently operational laboratories for the direct purpose of evaluating and analyzing any and all identified markers of tumorigenesis. These laboratories include: Human Tissue Research Center (tissue procurement, sectioning, and histology), Tissue Analysis Laboratories (conventional immunohistochemistry, in situ hybridization, high throughput tissue microarray), Molecular Pathology Laboratories (gene expression, chromosomal abnormalities, polymorphism, high throughput array-based mutation analysis), Immunoassay Laboratory (ELISA, Western blot analysis), and Cellular Analysis Laboratories (flow cytometry, cytology, chromosomal analysis, cytogenetics) These laboratories are all in the UCLA School of Medicine (the Department of Pathology and Laboratory Medicine, the Department of Human Genetics, and the Jonsson Comprehensive Cancer Center) and therefore, have an established interaction and collaboration. 2. Coordinate the infrastructure for a thoughtful, yet rapid and flexible mechanism for study design, implementation, data collection, and information analysis. This infrastructure consists of distinguished faculty at UCLA which includes: the Core Laboratory Directors, an Internal Advisory Board committed to assisting in project design and strategic planning, and Bioinformatics core with combined expertise in biostatistics, bioinformatics, and data analysis and mining, and a Pathology Consultation Core for correlation of pathology diagnosis with a marker expression. 3. Establish a "Development Study" which will specifically focus on the production of tumor- specific tissue arrays to be used as one of the high throughput techniques for tumor marker evaluation.

生物标志物验证实验室——被称为加州大学洛杉矶分校定义肿瘤标志物核心（D-TEC）——的目标是：1。为评估和分析任何和所有已确定的肿瘤发生标志物的直接目的，最佳地协调一个目前正在运作的实验室联盟。这些实验室包括：人体组织研究中心（组织获取、切片和组织学）、组织分析实验室（常规免疫组织化学、原位杂交、高通量组织微阵列）、分子病理学实验室（基因表达、染色体异常、多态性、高通量阵列突变分析）、免疫分析实验室（ELISA、Western blot分析）和细胞分析实验室(流式细胞术、细胞学、染色体分析、这些实验室都在加州大学洛杉矶分校医学院（病理学和检验医学系，人类遗传学系和Jonsson综合癌症中心），因此，有一个建立的互动和合作。2. 协调基础设施，为研究设计、实施、数据收集和信息分析提供周到、快速和灵活的机制。该基础设施由加州大学洛杉矶分校的杰出教师组成，其中包括：核心实验室主任，致力于协助项目设计和战略规划的内部顾问委员会，生物信息学核心，结合生物统计学，生物信息学，数据分析和挖掘方面的专业知识，以及病理学咨询核心，用于病理诊断与标志物表达的相关性。3. 建立一项“开发研究”，专门研究肿瘤特异性组织阵列的生产，作为肿瘤标志物评估的高通量技术之一。